2 results
Approved WMOPending
The primary objective is to characterize the change in the Pharmacodynamic (PD) biomarker, fecal calprotectin, during treatment with anrukinzumab.The secondary objectives include:* Characterization of the PK profile and total IL-13 of three multiple…
Not approvedWill not start
The primary objective of this study is to determine the efficacy of vitamin D supplementation on the severity of PN in patients with multiple myeloma.